For his achievements in cancer research, the cell biologist Prof. Michael N. Hall, from the Biozentrum of the University of Basel, has been awarded the Charles Rodolphe Brupbacher Prize 2019. The Prize Ceremony will take place on January 31, 2019, during the international Charles Rodolphe Brupbacher Symposium in Zurich.
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver and can also serve as a biomarker for the diagnosis and prognosis of liver cancer.
The protein complex mTORC2 controls cellular lipid and carbohydrate metabolism. Researchers from the Biozentrum of the University of Basel and the ETH Zurich have now succeeded in deciphering the 3D structure of this important protein complex. The results have recently been published in “eLife”.
Lipid, also known as fat, is an optimal energy source and an important cell component. Much is required for the rapid and uncontrolled growth of cancer cells. Researchers have now discovered that the protein mTOR stimulates the production of lipids in liver tumors.
Professor Michael N. Hall from the Biozentrum of the University of Basel receives the Lasker Basic Medical Research Award 2017 – one of the most distinguished honors in biomedical research.
On February 8th, 2017, the American National Foundation for Cancer Research announced that Michael N. Hall, Professor of Biochemistry at the Biozentrum of the University of Basel, has been selected as the winner of the 2017 Szent-Györgyi Prize for Progress in Cancer Research. The award recognizes his groundbreaking discovery of the protein kinase TOR – target of rapamycin – and its role in cell growth control and carcinogenesis.
A combination of a diabetes medication and an antihypertensive drug can effectively combat cancer cells. The team of researchers at the Biozentrum of the University of Basel has also reported that specific cancer cells respond to this combination of drugs.
The University of Geneva has awarded the biochemist Michael N. Hall, from the Biozentrum of the University of Basel, an honorary doctorate. With this distinction, the university is recognizing his outstanding scientific achievements and his continued commitment to the institution.
For a long time it has been known that the protein TOR – Target of Rapamycin – controls cell growth and is involved in the development of diseases such as cancer and diabetes. Researchers at the University of Basel’s Biozentrum together with scientists from ETH Zurich have now examined the structure of mammalian TOR complex 1 (mTORC1) in more detail. The scientists have revealed its unique architecture in their latest publication in “Science”.
